Skip to navigation Skip to content

Clinical Trial: UCSF MS and COVID-19 Immunity Study


Treatment mode of action: n/a
Number of Subjects: 200
Medication: n/a
Location: California
Institutions: University of California, San Francisco
675 Nelson Rising Lane
San Francisco, CA, 94158 Contact Information
Kira McPolin




MS treatment involves the use of medications that target the immune system, which can increase the risk of certain infections.  This study is being conducted to get a better understanding of how immunity to COVID-19 vaccination may be impacted by MS treatments.  

Criteria for enrolling
Participants should be ages 18-75, diagnosed with MS, and unvaccinated to COVID-19 at the time they enroll in the study.

Participants should have been untreated for the past six months, or have been treated for the past six months with one of these therapies:
o             Ofatumumab (Kesimpta)
o             Fingolimod (Gilenya)
o             Siponimod (Mayzent)
o             Ozanimod (Zeposia)
o             Dimethyl fumarate (Tecfidera or generic equivalent)
o             Natalizumab (Tysabri)

What does the study involve?
If you are eligible and agree to take part in this research study, the following will occur:
    Brief discussion of your MS medical history and your COVID-19 vaccination status.
    Scheduling of blood sample collection at three different time points:
    1.Before COVID-19 vaccination
    2.Two weeks after the final dose of an mRNA-based COVID-19 vaccine (Pfizer-BioNtech or Moderna) OR four weeks after the single dose adenoviral-based Johnson and Johnson vaccine
    3.Six months after the final dose of the COVID-19 vaccine

Blood sample collection will be completed at UCSF, through scheduling a home visit, or with a third-party company (ExamOne, a part of Quest Diagnostics).


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.